Cargando…
COVID-19 and Dermatology in Iran
COVID-19 infection may affect the individuals with many underlying conditions including skin diseases. This cross-sectional study was conducted to provide an overview regarding the prevalence of COVID-19 disease in the patients with several skin diseases. Overall, 703 patients with several skin dise...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129800/ https://www.ncbi.nlm.nih.gov/pubmed/34809776 http://dx.doi.org/10.1016/j.clindermatol.2021.05.022 |
_version_ | 1783694383192735744 |
---|---|
author | Mansouri, Parvin Farshi, Susan Nikkhah, Nahid Nobari, Niloufar Najar Chalangari, Reza Nilforoushzadeh, Mohammad Ali |
author_facet | Mansouri, Parvin Farshi, Susan Nikkhah, Nahid Nobari, Niloufar Najar Chalangari, Reza Nilforoushzadeh, Mohammad Ali |
author_sort | Mansouri, Parvin |
collection | PubMed |
description | COVID-19 infection may affect the individuals with many underlying conditions including skin diseases. This cross-sectional study was conducted to provide an overview regarding the prevalence of COVID-19 disease in the patients with several skin diseases. Overall, 703 patients with several skin diseases participated in the study and completed our online-designed questionnaire. Among the total participants, only 32(4.6%) subjects reported the COVID-19 infection. The prevalence rate was equal to 0.04%. In the patients with psoriasis, 14 out of 322 people (4.3%) developed the COVID-19. Three out of 159 patients (1.9%) with alopecia areata had been affected with the COVID-19 and 4 (5.2%) patients with vitiligo had caught the disease. Only one subject (2%) with the lichen planus, and 6 (6.8%) patients with other skin diseases had developed the COVID-19 but in the patients with GVHD (Graft Versus Host Disease), 4 (80%) out of 5 patients had caught the COVID-19 disease. The frequency of COVID-19 infection was low in the studied population however; more studies with larger sample size are needed to determine the exact prevalence of the infection in the patients with skin diseases undergoing the treatment with several systemic medications. |
format | Online Article Text |
id | pubmed-8129800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81298002021-05-18 COVID-19 and Dermatology in Iran Mansouri, Parvin Farshi, Susan Nikkhah, Nahid Nobari, Niloufar Najar Chalangari, Reza Nilforoushzadeh, Mohammad Ali Clin Dermatol COVID-19: Important Updates and Developments COVID-19 infection may affect the individuals with many underlying conditions including skin diseases. This cross-sectional study was conducted to provide an overview regarding the prevalence of COVID-19 disease in the patients with several skin diseases. Overall, 703 patients with several skin diseases participated in the study and completed our online-designed questionnaire. Among the total participants, only 32(4.6%) subjects reported the COVID-19 infection. The prevalence rate was equal to 0.04%. In the patients with psoriasis, 14 out of 322 people (4.3%) developed the COVID-19. Three out of 159 patients (1.9%) with alopecia areata had been affected with the COVID-19 and 4 (5.2%) patients with vitiligo had caught the disease. Only one subject (2%) with the lichen planus, and 6 (6.8%) patients with other skin diseases had developed the COVID-19 but in the patients with GVHD (Graft Versus Host Disease), 4 (80%) out of 5 patients had caught the COVID-19 disease. The frequency of COVID-19 infection was low in the studied population however; more studies with larger sample size are needed to determine the exact prevalence of the infection in the patients with skin diseases undergoing the treatment with several systemic medications. Elsevier Inc. 2021 2021-05-18 /pmc/articles/PMC8129800/ /pubmed/34809776 http://dx.doi.org/10.1016/j.clindermatol.2021.05.022 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | COVID-19: Important Updates and Developments Mansouri, Parvin Farshi, Susan Nikkhah, Nahid Nobari, Niloufar Najar Chalangari, Reza Nilforoushzadeh, Mohammad Ali COVID-19 and Dermatology in Iran |
title | COVID-19 and Dermatology in Iran |
title_full | COVID-19 and Dermatology in Iran |
title_fullStr | COVID-19 and Dermatology in Iran |
title_full_unstemmed | COVID-19 and Dermatology in Iran |
title_short | COVID-19 and Dermatology in Iran |
title_sort | covid-19 and dermatology in iran |
topic | COVID-19: Important Updates and Developments |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129800/ https://www.ncbi.nlm.nih.gov/pubmed/34809776 http://dx.doi.org/10.1016/j.clindermatol.2021.05.022 |
work_keys_str_mv | AT mansouriparvin covid19anddermatologyiniran AT farshisusan covid19anddermatologyiniran AT nikkhahnahid covid19anddermatologyiniran AT nobariniloufarnajar covid19anddermatologyiniran AT chalangarireza covid19anddermatologyiniran AT nilforoushzadehmohammadali covid19anddermatologyiniran |